Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
Status:
Terminated
Trial end date:
2007-02-07
Target enrollment:
Participant gender:
Summary
The combination of cisplatin and irinotecan has significant anti-tumor activity in esophageal
cancer. Oxaliplatin has been shown to have activity in combination with 5-Fluorouracil (5FU)
and radiation in treatment of locally advanced esophageal cancer. Oxaliplatin also has better
side effects profile than cisplatin and may be able to overcome tumors that have developed
cisplatin resistance. The standard treatment of locally advanced esophageal cancer has been
cisplatin, 5FU and radiation followed by possible esophagectomy. However, a large portion of
these patients will relapse and the tumor may develop resistance to cisplatin and/or the
cumulative toxicity from previous treatment forbids the use of cisplatin again. Weekly
combination of oxaliplatin and irinotecan has been shown to be active and well tolerated in
elderly population with refractory colorectal cancer. Therefore, we propose this phase II
trial of a weekly oxaliplatin and irinotecan to test the effectiveness and the tolerability
of this regimen in metastatic and/or recurrent esophageal cancer.